Şunu aradınız:: hypertyreose (Danca - İngilizce)

hypertyreose
hyperthyroidis m

hypertyreose/tyreotoksikose
hyperthyroidism/thyrotoxicosis

binyrebarkinsufficiens hypertyreose, hypotyreose
adrenal insufficiency hyperthyroidism, hypothyroidism

observerede autoimmune thyreoidea-lidelser omfatter hypertyreose eller hypotyreose.
observed autoimmune thyroid disorders included hyperthyroidism or hypothyroidism.

hypotyreose eller hypertyreose skal behandles efter gældende medicinsk praksis for at opretholde euthyroid tilstand.
hypothyroidism or hyperthyroidism should be treated according to standard medical practice to maintain euthyroid state.

patienter med eksisterende hypotyreose eller hypertyreose bør behandles efter gældende klinisk praksis, før behandling med sunitinib initieres.
patients with pre-existing hypothyroidism or hyperthyroidism should be treated as per standard medical practice prior to the start of sunitinib treatment.

der sås hypertyreose hos 4 (1,7%) patienter i sunitinibbehandling, men ikke hos patienter i capecitabinbehandling.
hyperthyroidism was reported in 4 (1.7%) sunitinib subjects and no capecitabine subjects.

der er rapporteret om sjældne tilfælde af hypertyreose, hvoraf enkelte har været efterfulgt af hypotyreose i kliniske undersøgelser samt efter markedsføring af sutent.
rare cases of hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through post-marketing experience.

skjoldbruskkirteldysfunktion der anbefales laboratorieundersøgelse af skjoldbruskkirtelfunktionen ved baseline, og patienter med hypotyreose eller hypertyreose bør behandles efter gældende medicinsk praksis, før behandling med sunitinib initieres.
thyroid dysfunction baseline laboratory measurement of thyroid function is recommended, and patients with hypothyroidism or hyperthyroidism should be treated as per standard medical practice prior to the start of sunitinib treatment.

der er rapporteret om tilfælde af hypertyreose, hvoraf enkelte har været efterfulgt af hypotyreose, og tyroiditis er blevet rapporteret med frekvensen ikke almindelig i kliniske studier samt efter markedsføring af sutent.
cases of hyperthyroidism, some followed by hypothyroidism, and cases of thyroiditis have been uncommonly reported in clinical trials and through post-marketing experience.

i et klinisk studie med axitinib til behandling af patienter med rcc, så man hypotyreose hos 20,9% af patienterne og hypertyreose hos 1,1% af patienterne.
in a controlled clinical study with axitinib for the treatment of patients with rcc, hypothyroidism was reported in 20.9% of patients and hyperthyroidism was reported in 1.1% of patients.

før godkendelse opstod der alvorlige tilfælde hos < 1 % af patienterne, hvor kun basedows sygdom (også kaldet graves’ sygdom), hypertyreose og hypotyreose blev observeret hos mere end 1 patient.
prior to authorisation, serious events occurred in <1% of patients, with only basedow’s disease (also known as graves’ disease), hyperthyroidism, and hypothyroidism occurring in more than 1 patient.